Paradigm Biopharmace

PAR
End-of-day quote AUSTRALIAN SECURITIES EXCHANGE LIMITED - 07/17
1.695AUD
-1.17%
Prev.1.6950
Open1.7050
High1.7550
Low1.6900
Volume258 910
Financials
Sales 2019 3,00 M
EBIT 2019 -6,00 M
Net income 2019 -5,80 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -44,6x
P/E ratio 2020 -39,4x
Capi. / Sales2019 109x
Capi. / Sales2020 109x
Capitalization 326 M
Company
Paradigm Biopharmaceuticals Limited is a biopharmaceutical company focused on repurposing the drug pentosan polysulfate sodium (PPS) for the treatment of inflammation. The Company is engaged in researching and developing therapeutic products for human use. The Company is a drug repurposing company,...
Sector :
Biopharmaceuticals
Calendar :
No events available
Latest news
05/30PARADIGM BIOPHARMACEUTICALS : receives more positive real-world patient data
AQ
05/10PARADIGM BIOPHARMACEUTICALS : IPPs drug reduces bone marrow lesions in hip, knee caps and ankles
AQ
04/18PARADIGM BIOPHARMACEUTICALS : secures $61.3 million in first stage of raising
AQ
04/16PARADIGM BIOPHARMACEUTICALS : Announces Launch Of A$77.9 Mn Capital Raise For Clinical Trials
AQ
04/16PARADIGM BIOPHARMACEUTICALS : phase 2b trial achieves key endpoints in OA of the knee
AQ
01/19PARADIGM BIOPHARMACEUTICALS : Mount Sinai Partners with Paradigm Biopharmaceuticals Ltd. and ReqMed Company, Ltd. to Repurpose Drug to Battle Rare MPS Diseases
AQ
2018PARADIGM BIOPHARMACEUTICALS : Positive Phase 2B Clinical Trial Results For iPPS Boost Paradigms Shares
AQ
2018PARADIGM BIOPHARMACEUTICALS : has results pending for phase 2b clinical trial
AQ
Technical analysis trends
Short TermMid-TermLong Term
TrendBullishNeutralBullish
Resistance1,752,021,92
Spread/Res.-3,1%-16%-12%
Spread/Supp.11%85%42%
Support1,530,921,20